Subscribe to our mailings!

Financing & Capital Markets

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

March 24, 2026

Biotechs Must Face Reality to Succeed in Today’s Funding Environment – Treehill Partners CEO in Biospace

Posted By: TreehillPartners
In: Financing & Capital Markets, Strategy & Corporate Development

March 5, 2026

JPM 2026 and Biotech’s New Reality – Treehill Partners CEO in Pharmaphorum

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

February 23, 2026

Scrip Asks – What Does 2026 Hold For Biopharma

Posted By: TreehillPartners
In: Leadership & Restructuring

February 19, 2026

Riding the Gene Therapy Rollercoaster into 2026 – Treehill CEO in Inside Precision Medicine

Posted By: TreehillPartners
In: Drug Development

November 15, 2024

Data Is The Underpinning of Healthcare – GEN interview with Ali Pashazadeh, Treehill Partners CEO

Posted By: TreehillPartners
In: Drug Development, Financing & Capital Markets, Strategy & Corporate Development

Read the full interview of Ali Pashazadeh, Treehill Partners CEO at Genetic Engineering & Biotechnology News (GEN) - a renown publication where GEN's unique news and technology focus covers the entire bioproduct life cycle...

February 9, 2026

Treehill Partners Featured in Cell & Gene Therapy Review’s 2026 Industry Predictions

Posted By: TreehillPartners
In: Drug Development

January 22, 2026

Oncology Investment – Treehill in Mergermarket

Posted By: TreehillPartners
In: Dealmaking

January 19, 2026

Scrip Asks – What Does 2026 Hold For Biopharma – Part 2

Posted By: TreehillPartners
In: Dealmaking, Drug Development

January 13, 2026

Clinical Trial Partners: Sink or Swim (JPM 2026 Series, Episode 2) – Treehill Partners on Onyx Newsroom

Posted By: TreehillPartners
In: Drug Development

January 9, 2026

Global Shifts And Strategic Resilience Will Shape CGT In 2026 – Treehill in Cell & Gene

Posted By: TreehillPartners
In: Drug Development

January 16, 2024

Scrip Asks… What Does 2024 Hold For Biopharma? – Treehill Partners CEO Ali Pashazadeh featured in Scrip’s annual outlook

Posted By: TreehillPartners
In: Financing & Capital Markets

Going into 2024, Treehill expects an even greater degree of scrutiny by boards and investors on the merits of deploying capital from the dwindling cash reserves to conducting clinical studies...

January 9, 2026

Scrip Asks – What does 2026 hold for Biopharma? Part 1

Posted By: TreehillPartners
In: Dealmaking

November 20, 2025

London Life Sciences Week – In-Depth Interview

Posted By: TreehillPartners
In: Drug Development

November 19, 2025

Manufacturing Flexibility

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

November 14, 2025

Treehill Partners Featured in FirstWord ExpertViews: The Convergence of Pharma and Biotech

Posted By: TreehillPartners
In: Strategy & Corporate Development

November 3, 2025

Pharma’s Path Through Industry Turbulence

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring

January 28, 2022

2021 in Retrospect and 2022 Outlook

Posted By: TreehillPartners
In: Dealmaking, Financing & Capital Markets

A month into 2022 and all virtual “JPM meetings” completed, we took a moment to reflect on the past

October 23, 2025

Neurology M&A – Treehill Quotes in Endpoints News

Posted By: TreehillPartners
In: Dealmaking

October 1, 2025

Treehill Partners CEO Featured in Newsweek Coverage of TrumpRx Initiative

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

September 30, 2025

Treehill Partners Experts Featured in FirstWord Report on Biomarkers in Rare Disease Therapies

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

September 11, 2025

Keep the Patients in Mind

Posted By: TreehillPartners
In: Leadership & Restructuring

September 5, 2025

Navigating Biotech’s Perfect Storm: Pharmaphorum Podcast

Posted By: TreehillPartners
In: Leadership & Restructuring, Strategy & Corporate Development

December 23, 2020

Biopharma Partnering: IPOs and Partnering

Posted By: TreehillPartners
In: Business Development & Licensing, Dealmaking, Financing & Capital Markets, Strategy & Corporate Development

An initial Public Offering has for decades been the endgame for an aspiring biotech company. Thinking back just 10 years, an IPO was conceivable generally only once a company had successfully brought at least one lead therapeutic into late-stage clinical trials and the pipeline was robust. Today this has changed...

August 22, 2025

Optimizing Biomanufacturing

Posted By: TreehillPartners
In: Drug Development

August 16, 2025

The Biotech Funding Model Needs a Major Overhaul

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

July 24, 2025

When VC Steps Back: Finding Alternative Biotech Funding

Posted By: TreehillPartners
In: Financing & Capital Markets, Strategy & Corporate Development

July 21, 2025

“We’re making the same mistakes over and over”

Posted By: TreehillPartners
In: Did you know?, Drug Development

July 21, 2025

Can Europe take the lead on biotech?

Posted By: TreehillPartners
In: Did you know?

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Subscribe to our mailings!

Financing & Capital Markets

Investment Patterns 2025 – BioSpace Podcast with Treehill Partners CEO

Will Biotech Still Be Relevant in 2030? – Treehill on Onyx Newsroom

Biotechs Must Face Reality to Succeed in Today’s Funding Environment – Treehill Partners CEO in Biospace

JPM 2026 and Biotech’s New Reality – Treehill Partners CEO in Pharmaphorum

Scrip Asks – What Does 2026 Hold For Biopharma

Riding the Gene Therapy Rollercoaster into 2026 – Treehill CEO in Inside Precision Medicine

Data Is The Underpinning of Healthcare – GEN interview with Ali Pashazadeh, Treehill Partners CEO

Treehill Partners Featured in Cell & Gene Therapy Review’s 2026 Industry Predictions

Oncology Investment – Treehill in Mergermarket

Scrip Asks – What Does 2026 Hold For Biopharma – Part 2

Clinical Trial Partners: Sink or Swim (JPM 2026 Series, Episode 2) – Treehill Partners on Onyx Newsroom

Global Shifts And Strategic Resilience Will Shape CGT In 2026 – Treehill in Cell & Gene

Scrip Asks… What Does 2024 Hold For Biopharma? – Treehill Partners CEO Ali Pashazadeh featured in Scrip’s annual outlook

Scrip Asks – What does 2026 hold for Biopharma? Part 1

London Life Sciences Week – In-Depth Interview

Manufacturing Flexibility

Treehill Partners Featured in FirstWord ExpertViews: The Convergence of Pharma and Biotech

Pharma’s Path Through Industry Turbulence

2021 in Retrospect and 2022 Outlook

Neurology M&A – Treehill Quotes in Endpoints News

Treehill Partners CEO Featured in Newsweek Coverage of TrumpRx Initiative

Treehill Partners Experts Featured in FirstWord Report on Biomarkers in Rare Disease Therapies

Keep the Patients in Mind

Navigating Biotech’s Perfect Storm: Pharmaphorum Podcast

Biopharma Partnering: IPOs and Partnering

Optimizing Biomanufacturing

The Biotech Funding Model Needs a Major Overhaul

When VC Steps Back: Finding Alternative Biotech Funding

“We’re making the same mistakes over and over”

Can Europe take the lead on biotech?

Will Biotech Still Be Relevant in 2030? – Treehill on Onyx Newsroom

Biotechs Must Face Reality to Succeed in Today’s Funding Environment – Treehill Partners CEO in Biospace

JPM 2026 and Biotech’s New Reality – Treehill Partners CEO in Pharmaphorum